Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The company is carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. Evgen Pharma’s objective is to become the leading company in the development of pharmaceuticals that activate the antioxidant response element, Nrf2.
Evgen Pharma’s core technology is Sulforadex®, a means of synthesising and concurrently stabilising the naturally occurring compound sulforaphane (or novel analogues based upon sulforaphane).
Sulforaphane is an established anti-cancer agent that benefits from a huge amount of peer-reviewed scientific literature identifying both its anti-cancer and neuroprotective characteristics. However, its commercial development as a potential prescription medicine has been prevented by the instability of the compound. Evgen Pharma’s Sulforadex® technology overcomes this problem by creating a stable version of sulforaphane, which can be delivered as a tablet or capsule.
Phase I studies of Evgen Pharma’s lead product, SFX-01, have already been successfully completed and it is currently in Phase II studies.
The potential of Sulforadex® has allowed Evgen Pharma to attract a highly experienced commercial, scientific and advisory team. The company is led by Chief Executive Dr Stephen Franklin, who has a track record in the commercialisation of intellectual property, and by Chairman Barry Clare, the former director of the Boots Company plc and head of its Boots Healthcare International business.
Evgen Pharma is a publicly quoted company which joined the AIM market of the London Stock Exchange in October 2015.